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Accepted 8 January 2016An electrochemical magnetoimmunosensor for the determination of estrogen receptor α (ERα) protein in com-
plex samples (serum and cell lysates) able to discriminate between ERα positive and negative breast cancer cells
is reported. Speciﬁcally functionalizedmagneticmicrobeadswith sandwich immunocomplexes and amperomet-
ric detection at disposable screen-printed carbon electrodes (SPCEs) resulted in highly selective and sensitive
ERα detection with a detection limit of 19 pgmL−1. This magnetoimmunosensing platformwas successfully ap-
plied to the quantitation of ERα in spiked human serum and cell lysates samples without any matrix effect with
an advantageous performance in terms of simplicity and assay times over commercial ELISA assays. The biosen-
sor capability for assessing ERα in intact breast cancer cells makes it competitive with conventional strategies
providing rapidly quantitative and reliable results on this relevant biomarker currently used in the clinical prac-
tice for diagnosis, follow-up and monitoring of metastatic breast cancer.
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Breast cancer1. Introduction
Breast cancer is the most frequently diagnosed cancer in women
worldwide, with nearly 1.4 million new cases annually and the leading
cause of cancer death despite the huge progress in treatment [9,25].
Numerous evidences have highlighted the importance of the estrogen
receptor (ER) in the progression and invasion of breast cancer cells
[28]. Indeed, approximately 70% of new diagnosed breast cancers are
ER positive [8].
Estrogen is a hormone playing important roles during mammary
gland development but also in the development, risk, and treatment
of breast cancer. It mediates its function by binding to and activating
both isoforms of estrogen receptors (ERα and ERβ, respectively)
in both, membrane and cytoplasm, producing their translocation to nu-
cleus, where ERα, and ERβ are ligand-dependent transcription factors
and regulate speciﬁc target genes [12]. ERα is the only isoform detect-
able by immunohistochemistry in breast cancer biopsies and is the1 394 29.
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. This is an open access article underpredominant subtype expressed in breast tumor tissues. Moreover, re-
cent ﬁndings suggest that this steroid receptor transcription factor
plays an important role in the biology of breast cancer and drives the
proliferation of breast cancer cells [27]. Furthermore, ERα levels in
breast tumor samples are highly predictive of a patient's response to
hormonal therapy [5]. Since ERα is rarely determined in normal breast
tissue from women without breast carcinoma and its levels and distri-
bution in biopsies of breast carcinomas are inﬂuenced by the age and
menopausal status of the patient, well-documented reference ranges
are not available [6]. However, a number of biochemical studies have
found values of 10 fmolmg−1 protein extract (by ligand binding assays)
or 15 fmol mg−1 protein (by enzyme immunoassays), to discriminate
between positive and negative ER tissues [13]. Regarding the serum
ERα levels, although clinically signiﬁcant cut-off values to discriminate
between receptor-positive and -negative breast cancer and their prog-
nostic value have not yet been established, Widschwendter et al. [24]
found, in a study with 182 breast cancer patients and 188 age-
matched controls, that serum ERα bioactivity was associated with the
presence of breast cancer and that women with ≥42.1 pg mL−1 serum
ERα bioactivity had a 2.47-fold risk for breast cancer and 2.70-fold risk
for ER-positive breast cancer, respectively. As a result, ERα has been
regarded as the most informative valuable marker for the diagnosis
and prognosis of breast cancer. Accordingly, the development of new
methods for ERα determination together with other breast cancer-the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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breast cancer patients, allowing their stratiﬁcation in well-deﬁned
groups of risk for guided and personalized treatment [16,27].
Traditional methods for the detection of ERα include enzyme-linked
immunosorbent assay (ELISA) [22], Western blotting [4] and immuno-
histochemistry [11]. Nevertheless, these methods usually present
some shortcomings. For example, immunohistochemistry andWestern
blotting provide typically semiquantitative results [19,23] while ELISA
can produce quantitative data but is time-consuming and expensive
[27].
Electrochemical biosensors represent a clear current alternative to
conventional methods in the clinical ﬁeld because of their simplicity of
use and inherent high selectivity and sensitivity. Moreover, they are
able to provide accurate quantitative determinations using cost-
effective instrumentation with pocket-size dimensions, ideal for inte-
gration in point-of-care (POC) devices [1,14]. Despite these excellent
features only one electrochemical DNA sensor has been reported for
the determination of ERα [27]. This biosensor involves the protection
of DNA duplex from Exonuclease III (Exo III)-mediated digestion by
speciﬁc binding of ERα to its DNA response elements and allowed
quantiﬁcation of ERα in the concentration range of 0.5 to 100 nMwith
a detection limit of 0.38 nM (25.1 ng mL−1). The electrochemical DNA
sensor was applied to interrogate the ERα levels in nuclear extracts
from different breast cancer cell lines but the electrode surface
modiﬁcation protocol was long (16.5 h) and the total assay time took
19 h [27,28]. To the best of our knowledge, no electrochemical
immunosensor has been so far reported for the determination of
ERα. This paper describes the ﬁrst electrochemical immunosensor for
the selective and sensitive determination of this clinically relevant bio-
marker. The proposed design implies the use of functionalizedmagnetic
beads (MBs) which have demonstrated to constitute powerful tools to
construct electrochemical immunosensors contributing to improve
their bioanalytical performance in terms of sensitivity, reduced assay
time and minimization of matrix effects which are essential to perform
determinations in complex matrices [20,26]. In this particular case,
the developed magnetoimmunosensor involves a sandwich conﬁgura-
tion using two sheep anti-human ERα antibodies. The capture antibody
was immobilized onto carboxylic acid-modiﬁed magnetic beads
(HOOC-MBs) whereas the biotinylated detector antibody was labeled
with a streptavidin-HRP conjugate. The electrochemical monitoring of
the afﬁnity reactions was carried out by amperometry at disposable
screen-printed carbon electrodes (SPCEs) using hydroquinone (HQ) as
electron transfer mediator and H2O2 as HRP substrate. The applicability
of the developed disposable magnetoimmunosensor was evaluated by
determining the target ERα protein in cell lysates and spiked human
serumaswell as by in vitromonitoring of the ERα status receptor in can-
cer cells. With the merits of simplicity, quick response, high sensitivity,
easy operation and low cost, the proposedmethod can overcome disad-
vantages of traditional methods and may have a positive impact in the
diagnosis and follow-up of breast cancer.
2. Materials and methods
2.1. Apparatus and electrodes
All electrochemical measurements were carried out in a μSTAT400
bipotentiostat/galvanostat from DropSens S.L. (Spain). Screen-printed
carbon electrodes (SPCEs) consisting of a 4 mm-diameter carbon
working electrode (WE), a carbon counter electrode (CE) and a silver
pseudo-reference electrode (RE) (Ref. DRP-C110) and the speciﬁc
cable connector (Ref. DRP-CAC) which acted as interface between the
SPCEs and the potentiostat were also supplied by Dropsens S.L. A
DynaMag-2 Magnet from Invitrogen (Spain) and a MixMate microtube
mixer from Eppendorf (Germany) were employed for the magnetic
separation and incubation of the MBs. A neodymium permanent mag-
net (diameter 4 mm) from AimanGZ (Spain) was integrated in acustom-made poly(methyl methacrylate) dock to capture the MBs
over the WE surface (see Fig. 1).
2.2. Reagents and solutions
Recombinant human ERα, sheep anti-human ERα (antiERα) and bi-
otinylated sheep anti-human ERα (biotin-antiERα) were obtained from
a Human Total ERα/NR3A1 DuoSet IC ELISA kit from R&D Systems Inc.
(Ref: DYC5715, Minneapolis, United States). Recombinant human pro-
gesterone receptor (PR) was obtained from Human Total Progesterone
R/NR3C3 DuoSet IC ELISA kit from R&D Systems Inc. (Ref: DYC
DYC5415, Minneapolis, United States), recombinant human ErbB2 pro-
tein was used from the ELISA Kit (ref. SEKA10004, Sino Biological Inc.,
China) and recombinant human TNFα protein was purchased from
PeproTech (Ref. AF-300-01 A, United Kingdom).
Bovine serumalbumin (BSA) and streptavidin conjugatedHRP enzy-
matic label (SAv–HRP) were from Jackson ImmunoResearch (Refs.
001000-161 and 016-030-084, respectively, United Kingdom). Pooled
human serum was purchased from Sigma-Aldrich (Ref: H4522, Spain).
Carboxylic acid-modiﬁed MBs (Ref: HOOC-MBs, 2.8 μm, 30 mg mL−1
Dynabeads M-270 Carboxylic Acid) were bought from Invitrogen
(Spain) and used as received.
N-hydroxysuccinimide (NHS), N-(3-dimethylaminopropyl)-N′-
ethylcarbodiimide (EDC), ethanolamine hydrochloride (ETA), hydro-
quinone (HQ) and Tween 20 were from Sigma-Aldrich (Spain).
Sodium di-hydrogen phosphate, di-sodium hydrogen phosphate,
tris(hydroxymethyl)aminomethane hydrochloride (Tris–HCl), 2-(N-
morpholino)ethanesulfonic acid (MES), sodiumchloride (NaCl) and po-
tassium chloride (KCl) were purchased from Scharlau (Spain).
Ethylenediamine Tetraacetate (EDTA) was from Fisher Bioreagents
(Spain). All other chemicals were of analytical grade and ultrapure
water (Millipore Milli-Q) was used throughout.
Several buffers were freshly prepared for the experiments:
0.01 M phosphate buffered saline at pH 7.5 containing 137 mM
NaCl and 2.7 mM KCl (PBS); PBS supplemented with 1% (w/v) BSA;
PBS containing 0.05% (w/v) Tween 20 (PBST); 50 mM MES buffer at
pH 5.0; 50 mM phosphate buffer at pH 6.0 (PB) and 100 mM Tris–
HCl buffer at pH 7.2.
Details about all the protocols used (MBs biofunctionalization and
sandwich immunoassay, amperometric measurements and sample
analysis) are described in detail in the Supporting information.
3. Results and discussion
The immunoassay fundamentals aswell as the electrochemical reac-
tions involved in the development of themagnetoimmunosensing plat-
form for ERα biomarker determination are schematically displayed in
Fig. 1. As can be observed, all the immunoreactions involved in the
sandwich-type assay occurred on the MBs surface. After magnetically
trapping the MBs bearing the immunoconjugates on the working elec-
trode surface, amperometric detection of the HRP enzymatically cata-
lyzed reduction current generated in the presence of the HQ/H2O2
redox system was carried out.
3.1. Optimization of experimental variables
The experimental parameters involved in the magnetoimmuno-
sensor preparation and functioning were optimized by taking the mag-
nitude of the amperometric responses measured in the absence and in
the presence of 1.0 ng mL−1 ERα standards as criteria of selection for
each variable.
The primary antibody concentrationwas optimizedby functionalizing
HOOC-MBs as described in the section on biofunctionalization of MBs (in
the Supporting Information) and sandwich immunoassay with primary
antibody concentrations ranging from0.0 to 9.0 μgmL−1 (3-fold serial di-
lutions). Fig. 2a shows that no major changes were observed for the
Fig. 1. SPCE inserted in the homemade poly(methyl methacrylate) dock with functionalized MBs on top of the working electrode together with the schematic representation of the
sandwich magnetoimmunocomplexes and the reactions involved in the electrochemical detection.
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sured in the presence of 1.0 ngmL−1 ERα increased signiﬁcantlywith the
antiERα loading until 1.0 μg mL−1 and then decreased which is mostFig. 2. Dependence of the amperometric responsesmeasured in the absence (black bars) and in
immobilized on COOH-MBs (a) and the biotinylated detector antibody concentration (b). Errolikely due to the sterically hindered binding of the antigen when high
amounts of capture antibody are immobilized [2]. In viewof these results,
a 1.0 μg mL−1 capture antibody concentration was chosen as optimal.the presence (white bars) of 1.0 ngmL−1 ERα solution with the capture antibody loading
r bars estimated as a triple of the standard deviation (n = 3).
Fig. 3. Determination of ERα in cell lysates. Amperometric responses measured with the
magnetoimmunosensor in the absence and in the presence of 2.5 μg of cell lysates.
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tween 0.0 and 9.0 μgmL−1 were tested and results for ERα positive and
negative standard solutions compared. As shown in Fig. 2b, while no
signiﬁcant current variations were produced in the absence of ERα,
the amperometric response increased sharply with biotin-antiERα
concentration up to 1 μg mL−1 and showed a much more moderate in-
crease for larger concentrations in the presence of ERα. Accordingly, a
1 μg mL−1 detection antibody concentration was also selected for sub-
sequent experiments.
With the aim of shortening the assay time as much as possible, the
inﬂuence of the incubation timewith the target protein was also evalu-
ated. Four different incubation times were tested: 30, 60, 120 min and
overnight (16 h). Fig. S1 shows that the larger the incubation time, the
larger the obtained amperometric response, suggesting a somehow
slowbiomolecule binding. As a compromise between appropriate sensi-
tivity and rapid methodology, a 60 min incubation time was chosen for
further experiments. However, it is important to note that if higher sen-
sitivities were required, longer incubation times could be used.
Furthermore, with the aim of simplifying as much as possible the
whole assayprotocol thus shortening the assay time, procedures involv-
ing different numbers of working steps were checked. These were: i) a
step-by-step protocol implying three sequential incubations in the stan-
dard/sample (60 min), biotinylated detection antibody (60 min) and
SAv-HRP (10min) solutions; ii) a two-step assay involving a 60min in-
cubation in a mixture solution containing the target protein and the
biotin-antiERα, followed by another 10 min incubation step in the
SAv-HRP solution; iii) a one-step assay with just a 60 min incubation
in a mixture solution containing all the bioreagents (target protein,
biotin-antiERα and SAv-HRP). Fig. S2 shows that the conventional
approach involving three independent incubation steps gave rise to
noticeably better results. Conversely, simpliﬁed assays with one or
two incubation steps, while offering quantiﬁable signals exhibited sig-
niﬁcantly reduced current responses. This effect can be attributed to
the lower target recognition efﬁciency as a consequence of increased
steric hindrancewhen all the immunoreagents weremixed in homoge-
neous solution or the target protein was incubated together with the
biotin-antiERα. Accordingly, a 3-step protocol was employed for the
implementation of the magnetoimmunosensor. However, it should be
remarked that when sensitivity was not an issue, the one step protocol
is able to provide results in only 30 min (once the anti-ERα were
prepared).
Other experimental variables used, such as incubation times, detec-
tion potential and volume of MBs used per assay have been chosen ac-
cording to optimization studies performed in our previous works [7,10].
3.2. Analytical characteristics
Under the selected experimental conditions, the calibration curve
shown in Fig. S3 was constructed for ERα standards. A linear relation-
ship (r=0.990) between themeasured current and the ERα concentra-
tion was found over the 63–2000 pg mL−1 range, with slope and
intercept values of (0.27± 0.01) nAmLpg−1 and (20± 10) nA, respec-
tively. The detection limit (LOD) and the determination limit (LQ), 19
and 63 pg mL−1, respectively, were calculated as the concentrations
corresponding to signals three and ten times larger than the blank stan-
dard deviation (n = 10), respectively. The reproducibility was evaluat-
ed by measuring 1.0 ng mL−1 ERα standard solutions with 5 different
magnetoimmunosensors prepared in the same manner. The low rela-
tive standard deviation (RSD) value obtained, 2.5%, indicated a great re-
producibility of the whole magnetoimmunosensor fabrication and the
signal transduction protocols.
3.3. Selectivity of the magnetoimmunosensor
To assess the speciﬁcity of the magnetoimmunosensor, cross-
reactivity tests were carried out against different human non-targetproteins such as PR, ErbB2 and TNFα. Fig. S4 compares the signals pro-
vided by the magnetoimmunosensor for 0 and 500 pg mL−1 ERα with
those for relatively high concentrated solutions (10 ng mL−1) of these
non-target proteins. As can be deduced from the obtained results, no
signiﬁcant interference was apparent in any case even at the large con-
centrations assayed thus proving the selectivity of the developed
magnetoimmunosensor.
3.4. Application to the determination of ERα in human serum and cell
lysates
The validity of the developed methodology for clinical analysis
was checked by analyzing spiked human serum samples. As stated in
the section on application to the analysis of real samples (in the
Supporting Information), serum samples were diluted down to 75% in
PBS buffer containing 1% BSA. The possible existence of a matrix effect
was tested by constructing a calibration plot from the serum diluted
sample adequately spiked with growing amounts of the standard ERα
solution up to 2000 pgmL−1. The slope value of the resulting linear cal-
ibration plot (r = 0.999) was 0.262 ± 0.006 nA mL pg−1. This slope
is statistically similar to that obtained with the buffered standard
ERα solutions (0.27 ± 0.01 nA mL pg−1) and, therefore, it could be
concluded that no signiﬁcant matrix effect was apparent whenworking
in scarcely diluted human serum samples. Accordingly, ERα quantiﬁca-
tion could be accomplished by simple interpolation of the measured
current for the sample into the calibration plot constructed with ERα
standards. The analysis of serum samples spiked with 500 and
2000 pg mL−1 ERα yielded recoveries of (95 ± 11) and (93 ± 9)%, re-
spectively. These results further demonstrated the selectivity of the
magnetoimmunosensor and its usefulness for the reliable determina-
tion of ERα at pgmL−1 levels in real human serumdespite the complex-
ity of these biological samples containing large amounts of other
proteins such as BSA (~50 mg mL−1).
The magnetoimmunosensor was also used as an in situ testing sys-
tem to interrogate the ERα levels in lysates of cancer cell lines as a
mimic of cancerous lysates. For this purpose, three different metastatic
breast cancer cell lines expressing varying levels of ERα were assayed:
MDA-MB-436, MCF-7 and SK-BR-3. Furthermore, the human primary
pancreatic adenocarcinoma BxPC3 cell line was also checked as a con-
trol. It should be highlighted that these determinations are particularly
challenging because of the high sensitivity required since the raw ly-
sates include a small amount of the target protein together with many
other cell components. Fig. 3 shows that themagnetoimmunosensor re-
sponse was slightly different with respect to the blank for SK-BR-3 and
MDA-MB-436 lysates while it was signiﬁcantly larger for MCF-7 as ex-
pected considering ERα over-expression in the MCF-7 cell line [3]. No
matrix effect was apparent for ERα determination when the lysate
amount used was equal or lower than 2.5 μg. Therefore, using 2.5 μg of
raw lysates, the target protein was determined by simple interpolation
of the amperometric signals measured from the lysates into the
calibration graph constructed with ERα standards. The obtained results
are summarized in Table 1. In addition, they are compared with those
provided by a commercial ELISA kit using the same immunoreagents.
The hypothesis test carried out demonstrated the absence of statistically
Table 1
Determination of the ERα (in pg μg−1) in cell lysates from different cancer cells with
the developed amperometric magnetoimmunosensor and comparison with the results
obtained by a commercial ELISA spectrophotometric kit. Data are presented in the form
of: conﬁdence interval (medium value ± t.s/√n) at the signiﬁcance level 0.05; RSD value
obtained for n = 3.
Cancer cell ELISA Magnetoimmunosensor
MCF-7 (21 ± 1); 2.0% (22 ± 2); 3.6%
MDA-MB-436 (5 ± 1); 8.4% (3.7 ± 0.8); 9.1%
SK-BR-3 (5.5 ± 0.8); 6.0% (5 ± 1); 8.2%
BxPC3 (2.6 ± 0.6); 9.1% (2.3 ± 0.4); 7.5%
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cell samples with both methods at the signiﬁcance level 0.05.
In order to validate the results, cancer cell lysates were also analyzed
by 10% SDS-PAGE with both Coomasie Blue staining and immunostain-
ing to assess the presence of ERα in these preparations. As can be ob-
served in Fig. S5, the target biomarker was noticeably overexpressed
in the MCF-7 cells [3].
Moreover, it is worth mentioning that the ERα concentration mea-
sured in the MCF-7 lysates, (332 ± 30) fmol mg−1, is in agreement
with those reported by other authors, 289.5 [21] and 285 fmol mg−1
[15]. These results demonstrated fairly well the usefulness of the
approach to accurately determine the target protein content even in
the presence of a large excess of other non-target cell components. In
addition, it is important to remark that the great sensitivity of the
magnetoimmunosensor allows useful amperometric responses to be
obtainedwith only 2.5 μg of ERα-overexpressing cells lysates in contrast
with the 20–50 μg required by conventional immunochemical assays
such as Western blotting to detect the target protein. Moreover, the
sensitivity demonstrated by the developed magnetoimmunosensor
in these experiments, able to quantify accurately ERα ranges between
35 (BxPC3 cells) and 332 (MCF-7 cells) fmol mg−1 in cell lysates, dem-
onstrated its potential for real applicability in clinical oncology since the
average level of ERα in breast cancer is about 37 fmol mg−1 [18].
3.5. In vitro detection of ERα-overexpressing cells
The feasibility of the methodology for the in vitro monitoring of
ERα status directly in the cancer cells was also explored. A signiﬁcantly
large response was obtained with the magnetoimmunosensor for the
MCF-7 breast cancer cells, small responses were observed for the SK-
BR-3 and MDA-MB-436 breast cancer cells, and a negligible response
was obtained for the BxCP3 control cells. Fig. 4 compares the ampero-
metric responses obtained forMCF-7 andMDA-MB-436 at two different
cell densities thus demonstrating that the magnetoimmunosen-
sor allowed for a clear discrimination between the ERα expression
levels in both cell lines. These results demonstrate the good selectivity
of the proposed sensor for the speciﬁc in vitro detection of ERα-
overexpressing cancer cells. By interpolating the amperometric signalsFig. 4. Assessment of ERα status of cancer cells by means of the developed
magnetoimmunosensor. Amperometric responses measured in the presence of
a) 12,500 and b) 62,500 cancer cells.obtained in these in vitro experiments into the ERα standard calibration
curve, a rough estimation of the target protein amount and the number
of ERα receptors per cell in theMCF-7 cells was possible. The results ob-
tained of (0.27± 0.06) fg cell−1 ERα protein and (2451± 548) ERα re-
ceptors cell−1 are in good agreementwith the number of ERα-receptors
per cell estimated by Pawlak et al. of 2551 ± 164 [17].
In order to demonstrate that the binding of antiERα-MBs to ERα-
expressing cell lines is speciﬁc and based only on ERα expression, the
antiERα-MBs were incubated with cultures from the different cell
lines assayed following the protocol described in the section on applica-
tion to the analysis of real samples (in the Supporting Information).
After performing the described washing steps and just before incubat-
ing with the detector antibody, the modiﬁed MBs were examined
with an optical microscope. Photomicrographs (representative pictures
are shown in Fig. 5) demonstrated that no MDA-MB-436 and BxPC3
cells appeared attached to the MBs. Moreover, only one SK-BR-3 cell
was visible while the MCF-7 sample showed numerous cells associated
with the MBs. These observations are in agreement with the weak ex-
pression of ERα in BxPC3, SK-BR-3 and MDA-MB-436 cells and the
high expression in MCF-7 cells.
3.6. Comparison with other electrochemical approaches and commercial
ELISA assays
Compared with the only electrochemical biosensor reported so far
for ERα determination [27], the major advantages of the methodology
reported in this work are the higher sensitivity and the much shorter
time needed to perform the assay (5 vs 19 h). The achieved LOD is
more than three orders of magnitude lower than that reported by Zhu
et al. (19 pg mL−1 vs 25.1 ng mL−1). These advantages are particularly
relevant in the clinical ﬁeld, where a relatively short assay time is very
attractive in order to implement a diagnostic tool able to provide reli-
able results in a few hours, and a better sensitivity is particularly rele-
vant when working with valuable but scarce biological samples.
On the other hand, although achieving a similar sensitivity, the
methodology developed with the electrochemical immunosensor is re-
markably faster than that appliedwith commercial ELISA spectrophoto-
metric kits. So, the whole detection process lasts about 2 h, while the
commercial kit needs 4 h (once the antiERα-MBs and the antiERα-
plate were prepared, respectively). Moreover, the spectrophotometric
methods are difﬁcult to be automated and hence hardly used in situ.
Conversely, the use of the disposable immunosensors simpliﬁed largely
the whole analytical procedure, requiring smaller sample volumes, and
may be easily automated and performed with portable and cost-
effective instrumentation which makes it a very attractive and user-
friendly tool to perform decentralized analysis and be incorporated in
the hospital routine. In this context, it is worth mentioning that the de-
velopedmagnetoimmunosensor greatly simpliﬁes the protocol particu-
larly in the determination in intact cells, since it does not require
seeding, quenching, ﬁxing and permeabilization of the cells like the
few commercial ELISAs recommended for this purpose.
4. Conclusions
In this work, the ﬁrst electrochemical immunosensor for the deter-
mination of ERα protein is reported. The novel magnetoscaffold in-
volves the use of a sandwich immunosensing conﬁguration, HOOC-
MBs and amperometric detection at SPCEs using the HQ/HRP/H2O2 sys-
tem. The magnetoimmunosensor exhibits an excellent analytical
performance in terms of sensitivity, selectivity and reliability of the
measurements in complex biological samples. These attractive analyti-
cal characteristics, which bring relevant improvements with respect to
commercial ELISA spectrophotometric kits in terms of simplicity and
assay time, allow the accurate determination of ERα in spiked human
serum and raw cell lysates. Moreover, this is the ﬁrst time that an elec-
trochemical biosensor is applied to monitor this hormonal receptor
Fig. 5. Representative photomicrographs obtained at 10× magniﬁcation with 5-μL drops of antiERα-MBs suspensions incubated with MDA-MB-436, MCF-7, SK-BR-3 and BxPC3 cancer
cells.
76 U. Eletxigerra et al. / Sensing and Bio-Sensing Research 7 (2016) 71–76status in intact breast cancer cells thus making it a promising tool to be
implemented in useful low-cost devices designed for diagnostic and
therapeutic action in breast cancer.
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